HRMY Harmony Biosciences Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HRMY

Price (delayed)

$32.94

Market cap

$1.91B

P/E Ratio

13.02

Dividend/share

N/A

EPS

$2.53

Enterprise value

$1.48B

?
Relative Growth: Rel. Growth: 63
Relative Strength: Rel. Strength: 42
Relative Valuation: Rel. Valuation: 77
Relative Profitability: Rel. Profitability: 87

Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves ...

Highlights
Harmony Biosciences Holdings's equity has increased by 26% YoY and by 4.6% from the previous quarter
The company's revenue rose by 21% YoY and by 3.5% QoQ
The stock's price to earnings (P/E) is 39% less than its 5-year quarterly average of 20.8 but 18% more than its last 4 quarters average of 10.8
Harmony Biosciences Holdings's EPS has decreased by 8% QoQ and by 5% YoY
Harmony Biosciences Holdings's net income has decreased by 8% from the previous quarter and by 4.7% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.harmonybiosciences.com
Peers: OPK ORGO

Key stats

What are the main financial stats of HRMY

HRMY stock price

How has the Harmony Biosciences Holdings stock price performed over time
Intraday
2.62%
1 week
4.6%
1 month
1.07%
1 year
-6.31%
YTD
-11.97%
QTD
17.6%

Financial performance

How have Harmony Biosciences Holdings's revenue and profit performed over time
Revenue
$899.11M
Gross profit
$688.25M
Operating income
$189.52M
Net income
$145.62M
Gross margin
76.5%
Net margin
16.2%
The company's revenue rose by 21% YoY and by 3.5% QoQ
The net margin has contracted by 21% YoY and by 11% from the previous quarter
The operating margin has declined by 19% year-on-year and by 12% since the previous quarter
The gross profit has grown by 18% YoY and by 2.7% from the previous quarter

Price vs fundamentals

How does HRMY's price correlate with its fundamentals

Growth

What is Harmony Biosciences Holdings's growth rate over time

Valuation

What is Harmony Biosciences Holdings stock price valuation
HRMY P/E details
P/E
13.02
P/B
2.09
P/S
2.12
EV/EBIT
6.98
EV/EBITDA
6.23
EV/Sales
1.64
The stock's price to earnings (P/E) is 39% less than its 5-year quarterly average of 20.8 but 18% more than its last 4 quarters average of 10.8
Harmony Biosciences Holdings's EPS has decreased by 8% QoQ and by 5% YoY
The stock's price to book (P/B) is 67% less than its 5-year quarterly average of 6.1 and 2.9% less than its last 4 quarters average of 2.1
Harmony Biosciences Holdings's equity has increased by 26% YoY and by 4.6% from the previous quarter
HRMY's P/S is 55% below its 5-year quarterly average of 4.6
The company's revenue rose by 21% YoY and by 3.5% QoQ

Efficiency

How efficient is Harmony Biosciences Holdings business performance
The ROE is down by 29% YoY and by 13% from the previous quarter
HRMY's return on assets is down by 25% year-on-year and by 12% since the previous quarter
Harmony Biosciences Holdings's return on sales has decreased by 18% YoY and by 11% QoQ
HRMY's return on invested capital is down by 12% since the previous quarter

Dividends

What is HRMY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRMY.

Financial health

How did Harmony Biosciences Holdings financials performed over time
HRMY's total assets is up by 20% year-on-year
The total liabilities has declined by 10% since the previous quarter but it rose by 8% year-on-year
The debt is 83% less than the equity
The debt to equity has declined by 29% year-on-year and by 11% since the previous quarter
Harmony Biosciences Holdings's equity has increased by 26% YoY and by 4.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.